Unpacking the Biosimilar Buzz

As industry experts, it’s the number one topic we’re being asked to comment on. While biosimilars have existed for many years, the topic has been gaining some serious new attention as AbbVie’s Humira—the number one selling drug in the U.S.—no longer has exclusivity in the market.   Will biosimilar competitors increase competition, lower drug costs and […]

Unpacking the Biosimilar Buzz Read More »